Switch theme
Sign up to access all valuation multiples
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
2010
898
LTM Revenue $174M
LTM EBITDA $13.1M
$176M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Organigram Global has a last 12-month revenue (LTM) of $174M and a last 12-month EBITDA of $13.1M.
In the most recent fiscal year, Organigram Global achieved revenue of $160M and an EBITDA of -$23.6M.
Organigram Global expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Organigram Global valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $174M | XXX | $160M | XXX | XXX | XXX |
| Gross Profit | $58.4M | XXX | $47.5M | XXX | XXX | XXX |
| Gross Margin | 34% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | $13.1M | XXX | -$23.6M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | -15% | XXX | XXX | XXX |
| EBIT | -$17.0M | XXX | -$35.7M | XXX | XXX | XXX |
| EBIT Margin | -10% | XXX | -22% | XXX | XXX | XXX |
| Net Profit | $3.9M | XXX | -$45.4M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | -28% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Organigram Global's stock price is $1.
Organigram Global has current market cap of $196M, and EV of $176M.
See Organigram Global trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $176M | $196M | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Organigram Global has market cap of $196M and EV of $176M.
Organigram Global's trades at 1.1x EV/Revenue multiple, and -12.4x EV/EBITDA.
Equity research analysts estimate Organigram Global's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Organigram Global has a P/E ratio of 49.7x.
See valuation multiples for Organigram Global and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $196M | XXX | $196M | XXX | XXX | XXX |
| EV (current) | $176M | XXX | $176M | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 13.5x | XXX | -12.4x | XXX | XXX | XXX |
| EV/EBIT | -10.3x | XXX | -5.7x | XXX | XXX | XXX |
| EV/Gross Profit | 3.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 49.7x | XXX | -6.2x | XXX | XXX | XXX |
| EV/FCF | -6.4x | XXX | -19.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOrganigram Global's last 12 month revenue growth is 19%
Organigram Global's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Organigram Global's rule of 40 is -90% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Organigram Global's rule of X is 55% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Organigram Global and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | -9% | XXX | XXX | XXX |
| EBITDA Growth | 71% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -90% | XXX | 10% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ascend Wellness Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Ayr Wellness | XXX | XXX | XXX | XXX | XXX | XXX |
| Cresco Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Grown Rogue | XXX | XXX | XXX | XXX | XXX | XXX |
| Green Thumb Indus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Organigram Global acquired XXX companies to date.
Last acquisition by Organigram Global was XXXXXXXX, XXXXX XXXXX XXXXXX . Organigram Global acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Organigram Global founded? | Organigram Global was founded in 2010. |
| Where is Organigram Global headquartered? | Organigram Global is headquartered in United States of America. |
| How many employees does Organigram Global have? | As of today, Organigram Global has 898 employees. |
| Who is the CEO of Organigram Global? | Organigram Global's CEO is Ms. Beena Goldenberg. |
| Is Organigram Global publicy listed? | Yes, Organigram Global is a public company listed on NAS. |
| What is the stock symbol of Organigram Global? | Organigram Global trades under OGI ticker. |
| When did Organigram Global go public? | Organigram Global went public in 2014. |
| Who are competitors of Organigram Global? | Similar companies to Organigram Global include e.g. Ascend Wellness Holdings, Ayr Wellness, Cresco Labs, Grown Rogue. |
| What is the current market cap of Organigram Global? | Organigram Global's current market cap is $196M |
| What is the current revenue of Organigram Global? | Organigram Global's last 12 months revenue is $174M. |
| What is the current revenue growth of Organigram Global? | Organigram Global revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of Organigram Global? | Current revenue multiple of Organigram Global is 1.0x. |
| Is Organigram Global profitable? | Yes, Organigram Global is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Organigram Global? | Organigram Global's last 12 months EBITDA is $13.1M. |
| What is Organigram Global's EBITDA margin? | Organigram Global's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of Organigram Global? | Current EBITDA multiple of Organigram Global is 13.5x. |
| What is the current FCF of Organigram Global? | Organigram Global's last 12 months FCF is -$27.5M. |
| What is Organigram Global's FCF margin? | Organigram Global's last 12 months FCF margin is -16%. |
| What is the current EV/FCF multiple of Organigram Global? | Current FCF multiple of Organigram Global is -6.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
